Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: A cost-consequence model

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 333-341

  Grant, David M ^a   Mauskopf, Josephine A ^b   Bell, Larry ^c   Austin, Randall ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Independent Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; HEALTH CARE COST; HERPES ZOSTER; HOSPITALIZATION; HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ACYCLOVIR; AGED; ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; HERPES ZOSTER; HUMANS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; VALINE;

EID: 0030982838     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ragozzino MW, Melton III LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61(5):310-16.
2. Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for post-herpetic neuralgia in the UK. PharmacoEconomics 1994;6(2):142-8.
3. Wood MJ, Kay R, Dworkin R, Soong S-J, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7.
4. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir, after escalating single-and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
5. Huff JC, Bean B, Balfour HH Jr, et al. Therapy for herpes zoster with oral acyclovir. Am J Med 1988;85:84-9.
6. Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella zoster virus infections. Pharmacotherapy 1995; 15(5):49S-58.
7. Stergachis A. Overview of cost-consequence modeling in outcomes research. Pharmacotherapy 1995;15(5):40S-2.
8. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987:2-3.
9. Beutner KR, Friedman DJ, Forszpaniak C, et al. Improved therapy for herpes zoster in immunocompetent adults: valaciclovir compared with acyclovir. Antimicrob Agents Chemother 1995;39(7):1546-53.
10. Glaxo Wellcome Co. Valtrex (valaciclovir hydrochloride) caplets package insert. Research Triangle Park, NC; 1996.
11. Snesil NR, ed. 1995 red book. Montvale, NJ: Medical Economics, 1995.
12. Anonymous. Medical care consumer price index. Monthly Labor Rev 1995;118(9):90.
13. U.S. Bureau of the Census. Statistical abstract of the United States, 114th ed. Washington, DC: Author, 1994.
14. American Medical Association. Physician current procedural terminology: CPT-94. Chicago: Author, 1993:16, 34.
15. American Medical Association. Medicare physician payment reform: the physician's guide, vol 2. Chicago: Author, 1992: 222-3.
16. Anonymous. Employment compensations cost index for civilian workers. Monthly Labor Rev 1995;118(9):80.
17. Mauskopf J, Austin R, Dix L, Berzon R. The Nottingham health profile as a measure of quality of life in zoster patients: convergent and discriminant validity. Qual Life Res 1994;3:431-5.